A new Form 4 filing shows Erez Chimovits, a Director and 10%+ Owner of Braveheart Bio, Inc. (BRVE), purchased 1,666,667 shares on the open market on 2026-08-07 at $18.00 per share, a total outlay of $30,000,006.00. Following the purchase, Chimovits holds 11,901,826 shares indirectly, through a trust or entity structure rather than in a personal account.
This is not an isolated trade. The filing is part of a broader pattern our tracking has flagged as a cluster buy: two separate open-market purchases of Braveheart Bio stock, both dated 2026-08-07, adding up to $34,920,000 in combined insider spending. When multiple insiders step into the market on the same day with purchases of this size, it tends to draw more scrutiny than a single transaction would on its own, simply because it signals more than one party with direct knowledge of the company reaching the same conclusion at the same time.
Who Else Bought In
We previously covered another leg of this same cluster in our report on Forbion’s purchase, detailed in Forbion Buys $34.6M of Braveheart Bio (BRVE) Stock. Braveheart Bio has also seen insider buying interest from OrbiMed around the same period, covered separately on this site, underscoring that Chimovits’ purchase did not happen in a vacuum. Taken together, the filings paint a picture of concentrated, same-day buying from parties with board-level or ownership-level access to the company.
The size of Chimovits’ individual purchase, $30 million, is notable on its own for a company of Braveheart Bio’s profile, and the fact that it lands within a two-purchase cluster totaling nearly $35 million adds context that a standalone filing would not convey. The shares were acquired directly from the open market rather than through options exercises or grants, meaning Chimovits paid cash at prevailing market prices for the position.
Academic research on insider trading has found that clustered purchases, multiple insiders buying within a short window, are more strongly correlated with subsequent outperformance than isolated single-insider trades, though this correlation is a statistical pattern observed across large datasets and not a prediction about any individual company. Braveheart Bio’s Form 4 disclosures for August 7, 2026 will remain part of the public record, and additional filings tied to this cluster, if any emerge, will be reflected in our ongoing coverage of insider activity at the company.
→ See all BRVE coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.